On September 5, 2026, clinical oncology teams and patient advocacy networks reaffirmed Zejula® (Niraparib 100 mg film-coated tablets) as a cornerstone targeted maintenance therapy for adult patients battling advanced ovarian, fallopian tube, and primary peritoneal cancers. As an orally active, highly potent poly (ADP-ribose) polymerase (PARP) inhibitor developed by GlaxoSmithKline (GSK), Zejula provides substantial progression-free survival (PFS) extension following response to platinum-based chemotherapy regimens.

Through Onco Medicine, certified original GlaxoSmithKline packs of Zejula Niraparib 100mg Tablets 56's are made accessible to oncology hospitals, prescribing physicians, and named patients globally via GDP-certified cold-chain export, validated Certificate of Analysis (COA) batch release, and international personal importation pathways.

Key Clinical Pharmacology & Mechanism of Action

Zejula (niraparib) operates through selective inhibition of both PARP-1 and PARP-2 enzymes. These nuclear proteins are essential for repairing single-strand breaks in cellular DNA via the base excision repair (BER) pathway:

• PARP Enzyme Trapping: Niraparib traps PARP-1 and PARP-2 enzymes at sites of DNA damage, preventing normal enzyme release and blocking DNA replication forks.
• Synthetic Lethality: In cancer cells with homologous recombination deficiency (HRD)—such as those harboring BRCA1 or BRCA2 mutations or non-BRCA genomic instability—the inability to repair resulting double-strand DNA breaks causes catastrophic genomic instability and selective tumor cell apoptosis, leaving non-cancerous repair-competent cells viable.
• Broad Response Profile: Unlike earlier generation targeted agents, pivotal Phase 3 trials (such as the PRIMA and NOVA studies) demonstrated clinically meaningful PFS improvements across both HRD-positive and HRD-proficient/biomarker-negative patient cohorts in first-line and platinum-sensitive recurrent maintenance settings.

Individualized Starting Dose (ISD) Protocol

To optimize clinical efficacy while significantly mitigating high-grade hematologic adverse reactions (notably thrombocytopenia and neutropenia), modern oncologic guidelines mandate an Individualized Starting Dose (ISD) based on baseline patient weight and platelet parameters:

• Baseline Body Weight ≥ 77 kg AND Platelet Count ≥ 150,000/μL: Recommended starting dose is 300 mg once daily (three 100 mg tablets taken orally at bedtime).
• Baseline Body Weight < 77 kg OR Platelet Count < 150,000/μL: Recommended starting dose is 200 mg once daily (two 100 mg tablets taken orally at bedtime).
• Administration Guidelines: Film-coated tablets must be swallowed whole with water, with or without food. Bedtime dosing is frequently recommended by clinicians to alleviate potential early nausea or gastrointestinal discomfort.

Laboratory Monitoring & Safety Standards

Patient safety protocols require rigorous baseline and periodic clinical monitoring during Zejula therapy:

• Complete Blood Count (CBC): Weekly monitoring for the first month of therapy, monthly for the remaining first year, and periodically thereafter to guide dose modifications, treatment interruptions, or reductions if required.
• Cardiovascular Metrics: Monthly blood pressure and heart rate evaluations, especially during the initial three months of treatment.
• Prescription Storage: Store in original carton at room temperature below 30°C (86°F), protected from excessive heat and direct moisture.

Global Named-Patient Sourcing via Onco Medicine

For international patients facing domestic supply chain shortages, protracted national formulary delays, or prohibitive retail markups, Onco Medicine facilitates direct, fully compliant cross-border procurement of genuine GlaxoSmithKline Zejula 100 mg (56 compresse rivestite con film):

• Regulatory Authorization: Coordinated under official personal import programs including US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), ANVISA RDC exemptions, and Saudi SFDA personal clearance frameworks.
• Authenticity Verification: Every unit is sourced strictly through licensed European and UK pharmaceutical distributors, accompanied by manufacturer batch testing reports, tamper-evident security seals, and verifiable Certificates of Analysis (COA).
• Rapid Climate-Secure Transit: Express courier dispatch with real-time temperature tracking and delivery directly to specialized cancer centers, hospital pharmacies, or registered residential addresses within 4 to 8 business days worldwide.

Inquire with our clinical oncology desk for batch availability, pricing inquiries, and country-specific customs documentation support: support@onco-medicine.com or speak directly with our oncology pharmacists via WhatsApp (+91 94275 19809).